Orion or ORIEN – The whole is greater than the parts

I am a bit of an astronomy buff.   When my kids were younger, I had an eight inch reflecting telescope I would set up in the backyard.  My kids and I would invite other families in the neighborhood to look at the night sky.  I recall one evening, we talked about the night sky while I was setting up.  The constellation Orion was particularly beautiful that evening.  We discussed about how the stars that make up Orion’s belt, legs, shoulders and sword, tell us a story we would not understand if we just looked through the telescope at each star separately.   We still wanted to look through the telescope (Orion’s sword was particularly interesting), but looking at the constellation as a whole told us an additional story.  The whole was greater than the parts.

Continue reading

Biden’s next silo?

Vice President Biden spoke recently about how he will spend his time when he leaves government in a few weeks.  The “Cancer Moonshot” will be behind him, but his dedication to the cause of reducing the burden of cancer will not.  Through his Cancer Moonshot, he has spoken with passion and eloquence about the importance of breaking down cancer research silos that limit our ability to share information about the genetics of cancer.  He has challenged us to change our culture and develop new collaborative models for cancer research.

He also expressed concerns about the economics of cancer therapy.   More specifically, as we develop better cancer therapeutics, can we afford them?  This is one of the items he will address when his term as Vice President comes to an end.

Continue reading

Rejuvenation of failed cancer research hypotheses

I just returned from one of my favorite meetings of the year, the annual American Society of Hematology (ASH) meeting that I have attended almost every year since becoming a cancer researcher  in the late 1980s.   At the ASH annual meeting, research and clinical advances in blood cancers and other blood disorders are presented and discussed by scientists and physicians.   Several presentations at this year’s meeting led me to think about my first ASH meetings.

Continue reading

Disruptive Innovation in Cancer Medicine – See Cancer Differently

We are in a remarkable time in cancer medicine. The investment in cancer research over the past several decades has helped us in our understanding of the biology of malignant cells, and how such cells interact with their microenvironment, especially the immune system. We have learned that cancer is more complex at the molecular level more than we ever imagined.

Continue reading

Cancer moonshot – all systems “go”

About a year ago, I blogged about “going to the moon” as a metaphor for cancer research. More recently, the phrase “cancer moonshot” has taken on new meaning. In his state-of-the-union address, President Obama charged Vice President Biden with refocusing the nation’s effort on cancer and cancer research. To quote the President – “Vice President Biden said that with a new moonshot, America can cure cancer… I’m putting Joe in charge of Mission Control.” The cancer research community was already energized by the amazing potential for cancer research to reduce the pain and suffering caused by cancer at this particularly point in time, and welcomed the renewed focus on cancer research. Nevertheless, there was also a degree of skepticism. Many wondered whether the “cancer moonshot” was another example of politicians over-simplifying the incredible challenge of cancer in the short term. They worried that the result would be raised expectations without significant change or meaningful acceleration of progress in the long term.

Continue reading

Cancer immunotherapy, research funding, and new cancer drugs – a year in review

It has been a while since I submitted a blog entry, and one of my New Year’s resolutions is that I will get back to posting entries more regularly. I thought I would start with a summary of the past year in the field of cancer in general and the Holden Comprehensive Cancer Center in particular.
Continue reading

Addressing complex, painful, inescapable truths

I spent an evening last week doing two things that, at first, I thought were unrelated.

First, I viewed a preview of “Cancer: The Emperor of All Maladies,” a PBS documentary based on the book by Siddhartha Mukherjee. His preview was sponsored by the Iowa Cancer Consortium, The American Cancer Society, The Iowa Department of Public Health and Iowa Public Television. It included excerpts from the 3 part PBS documentary by producer Ken Burns that starts tonight, March 30 and runs through Wednesday, April 1. The preview was followed by a panel discussion. My fellow panelists and I made brief statements, and then entertained a range of outstanding questions from the audience.

Continue reading

Beautiful hypothesis – ugly fact

Dr. Laura Rogers, a post-doc in my research lab, likes to start her presentations during our weekly research laboratory meetings with a quote. One she used a few months back was from Thomas Huxley, a renowned British biologist from the 1800s, who said, “The great tragedy of science – the slaying of a beautiful hypothesis by an ugly fact.” It was a very appropriate quote for Laura to use given the results we were discussing that day.

As Huxley’s quote illustrates, Laura wasn’t the first scientist to see a beautiful hypothesis slain by an ugly fact, and she will not be the last.

Continue reading

Hope Without Hype

Last week, I had the honor of moderating a panel discussion on Capitol Hill on behalf of the Association of American Cancer Institutes and the American Association for Cancer Research. This panel was sponsored by the congressional cancer caucus and focused on the importance of the nation’s premier cancer research centers. In such settings, it can be challenging to talk about the vital importance of the work done at our cancer centers in a way that highlights the hope without appearing to be resorting to hype.

Continue reading